{"id":"levetiracetam-lev","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Somnolence"},{"rate":"10-15","effect":"Asthenia/fatigue"},{"rate":"10-15","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"5-15","effect":"Behavioral/mood changes (irritability, anxiety)"},{"rate":"5-10","effect":"Ataxia"},{"rate":"5-10","effect":"Infection"}]},"_chembl":null,"_dailymed":{"setId":"2b37c579-ebe7-4ce1-8a34-03e974a77439","title":"LEVETIRACETAM (LEVETIRACETAM IN SODIUM CHLORIDE) INJECTION [SOMERSET THERAPEUTICS, LLC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Levetiracetam is a pyrrolidone derivative that binds to the synaptic vesicle protein SV2A, which is involved in vesicle exocytosis and neurotransmitter release. This binding reduces the release of excitatory neurotransmitters and stabilizes neuronal membranes, thereby suppressing seizure propagation. Unlike many other antiepileptic drugs, it does not directly interact with ion channels or GABA receptors.","oneSentence":"Levetiracetam reduces neuronal excitability and seizure activity through binding to synaptic vesicle protein SV2A, modulating neurotransmitter release.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:24.014Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Partial-onset seizures (adjunctive therapy)"},{"name":"Myoclonic seizures in juvenile myoclonic epilepsy (adjunctive therapy)"},{"name":"Primary generalized tonic-clonic seizures (adjunctive therapy)"}]},"trialDetails":[{"nctId":"NCT06907173","phase":"PHASE3","title":"Ketamine add-on Therapy for Established Status Epilepticus Treatment Trial (KESETT)","status":"RECRUITING","sponsor":"University of Virginia","startDate":"2026-02","conditions":"Status Epilepticus","enrollment":770},{"nctId":"NCT07477431","phase":"PHASE2","title":"Levetiracetam for Persons at Risk for Alzheimer's Disease","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2025-10-23","conditions":"Hippocampal Hyperactivation, Prodromal Alzheimer Disease","enrollment":40},{"nctId":"NCT07234695","phase":"PHASE3","title":"LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome","status":"RECRUITING","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2025-12-22","conditions":"Down Syndrome, Down Syndrome (DS), Down Syndrome (Trisomy 21)","enrollment":120},{"nctId":"NCT02229123","phase":"PHASE2","title":"Levetiracetam Treatment of Neonatal Seizures: Safety and Efficacy Phase II Study","status":"COMPLETED","sponsor":"University Hospital, Tours","startDate":"2018-02-27","conditions":"Neonatal Seizures","enrollment":18},{"nctId":"NCT05610085","phase":"PHASE2","title":"A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2023-03-24","conditions":"Neonatal Seizure, Neonatal Encephalopathy, Hypoxic-Ischemic Encephalopathy","enrollment":133},{"nctId":"NCT07052136","phase":"NA","title":"Efficacy Comparison Between Levetiracetam and Valproic Acid in Pediatric Patients With Status Epilepticus","status":"COMPLETED","sponsor":"RESnTEC, Institute of Research","startDate":"2024-11-01","conditions":"Status Epilepticus","enrollment":138},{"nctId":"NCT06773364","phase":"PHASE3","title":"Early Initiated Ambulance-delivered Levetiracetam and Headposition in Hyper-acute Stroke Trial","status":"RECRUITING","sponsor":"Shanghai East Hospital","startDate":"2025-04-30","conditions":"Suspected Stroke","enrollment":2423},{"nctId":"NCT05450978","phase":"","title":"Physiological-based Pharmacokinetics Approach to Medication Exposure During Pregnancy and Breastfeeding","status":"RECRUITING","sponsor":"University of Pittsburgh","startDate":"2022-07-20","conditions":"Epilepsy, Pregnancy Related","enrollment":60},{"nctId":"NCT03340064","phase":"PHASE3","title":"A Study of Levetiracetam as Monotherapy or Adjunctive Treatment of Partial Seizures in Pediatric Epileptic Subjects Ranging From 1 Month to Less Than 4 Years of Age","status":"COMPLETED","sponsor":"UCB Japan Co. Ltd.","startDate":"2017-11-30","conditions":"Partial Seizures","enrollment":38},{"nctId":"NCT03325439","phase":"PHASE3","title":"A Study to Test the Pharmacokinetics, Efficacy, and Safety of Brivaracetam in Newborns With Repeated Electroencephalographic Seizures","status":"TERMINATED","sponsor":"UCB Biopharma SRL","startDate":"2019-05-07","conditions":"Electroencephalographic Neonatal Seizures","enrollment":9},{"nctId":"NCT00150709","phase":"PHASE3","title":"A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"1998-01-26","conditions":"Epilepsy, Partial","enrollment":223},{"nctId":"NCT04559529","phase":"PHASE2","title":"Pharmacological Modulation of Hippocampal Activity in Psychosis 2","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2020-09-23","conditions":"Schizophrenia; Psychosis","enrollment":62},{"nctId":"NCT00152503","phase":"PHASE2","title":"Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking Levetiracetam","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2005-08-31","conditions":"Epilepsy, Partial","enrollment":59},{"nctId":"NCT03436433","phase":"PHASE2","title":"Seizure Prophylaxis in Patients With Glioma or Brain Metastasis","status":"TERMINATED","sponsor":"Duke University","startDate":"2019-01-31","conditions":"Glioma, Glioma of Brain, Brain Tumor","enrollment":4},{"nctId":"NCT04277936","phase":"PHASE2","title":"Pharmacologic Modulation of Hippocampal Activity in Psychosis","status":"TERMINATED","sponsor":"Vanderbilt University Medical Center","startDate":"2020-05-11","conditions":"Schizophrenia; Psychosis","enrollment":1},{"nctId":"NCT04759196","phase":"PHASE4","title":"Generating Evidence on NonEpileptic, Stereotypical and Intermittent Symptoms (NESIS) in Chronic Subdural Hematomas","status":"UNKNOWN","sponsor":"Université de Sherbrooke","startDate":"2021-03-01","conditions":"Chronic Subdural Hematoma, Epilepsy; Seizure, Cortical Depression; Cortical Depolarization","enrollment":56},{"nctId":"NCT00615615","phase":"PHASE3","title":"Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"1999-09","conditions":"Epilepsy","enrollment":216},{"nctId":"NCT00150748","phase":"PHASE3","title":"Long Term Follow up Treatment With Levetiracetam in Subjects of 4 Years and Older With Generalized Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2001-11","conditions":"Generalized Epilepsy","enrollment":217},{"nctId":"NCT04425798","phase":"","title":"Connectivity Alterations After Levetiracetam Application","status":"UNKNOWN","sponsor":"Beijing Neurosurgical Institute","startDate":"2022-05-25","conditions":"Glioma, Epilepsy","enrollment":30},{"nctId":"NCT03695094","phase":"PHASE1","title":"A Study in Participants With Epilepsy, to Evaluate the Pharmacokinetics, Safety and Tolerability of Oxcarbazepine on Padsevonil","status":"COMPLETED","sponsor":"UCB Biopharma S.P.R.L.","startDate":"2018-09-18","conditions":"Epilepsy","enrollment":31},{"nctId":"NCT01720667","phase":"PHASE1, PHASE2","title":"Efficacy of Intravenous Levetiracetam in Neonatal Seizures","status":"COMPLETED","sponsor":"Richard H. Haas","startDate":"2013-03","conditions":"Neonatal Seizures","enrollment":280},{"nctId":"NCT01137110","phase":"NA","title":"Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After aSAH","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2010-05-01","conditions":"Subarachnoid Hemorrhage","enrollment":84},{"nctId":"NCT03953781","phase":"","title":"Effect of Valproate Versus Levetiracetam Monotherapy on Reproductive Functions in Epileptic Males","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2016-06-01","conditions":"Epilepsy","enrollment":50},{"nctId":"NCT03580707","phase":"PHASE2, PHASE3","title":"Does BRV Have Faster Onset Time & Greater Effect Than LEV in Epilepsy Pts Using PPR Pharmacodynamic Efficacy Endpoint","status":"COMPLETED","sponsor":"Rosenfeld, William E., M.D.","startDate":"2018-06-01","conditions":"Photosensitive Epilepsy","enrollment":16},{"nctId":"NCT00916149","phase":"NA","title":"Cognitive Effects of Treatment of Interictal Discharges","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2007-01","conditions":"Epilepsy","enrollment":31},{"nctId":"NCT01653262","phase":"PHASE3","title":"Effect of Brivaracetam (BRV) on Nonpsychotic Behavioral Side Effects in Subjects Treated Previously With Levetiracetam (LEV)","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2012-07","conditions":"Epilepsy","enrollment":29},{"nctId":"NCT00774306","phase":"NA","title":"Antiepileptic Drugs and Vascular Risk Markers","status":"TERMINATED","sponsor":"Thomas Jefferson University","startDate":"2009-04","conditions":"Subarachnoid Hemorrhage","enrollment":52},{"nctId":"NCT02602860","phase":"PHASE1","title":"A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2015-11","conditions":"Healthy Volunteers","enrollment":13},{"nctId":"NCT02726867","phase":"PHASE3","title":"Levetiracetam, Lacosamide and Ketamine as Adjunctive Treatment of Refractory Status Epilepticus","status":"WITHDRAWN","sponsor":"Mid-Atlantic Epilepsy and Sleep Center, LLC","startDate":"2014-02","conditions":"Epilepsy, Status Epilepticus","enrollment":""},{"nctId":"NCT01375374","phase":"PHASE3","title":"Hormonal and Lipid Levels in Male Subjects After a Switch From Carbamazepine to Lacosamide","status":"TERMINATED","sponsor":"UCB Pharma","startDate":"2011-07","conditions":"Epilepsy, Partial","enrollment":11},{"nctId":"NCT01954121","phase":"PHASE3","title":"Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2013-09","conditions":"Epilepsy, Partial Seizures","enrollment":436},{"nctId":"NCT01229735","phase":"PHASE4","title":"Levetiracetam Versus Topiramate as Adjunctive Therapy to Evaluate Efficacy and Safety in Subjects With Refractory Partial Onset Seizures","status":"COMPLETED","sponsor":"UCB Korea Co., Ltd.","startDate":"2010-11","conditions":"Epilepsy","enrollment":343},{"nctId":"NCT02815410","phase":"PHASE2","title":"Validation of the Role of Levetiracetam for Newly Diagnosed GBM Patients","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2016-07","conditions":"Glioblastoma Multiforme","enrollment":73},{"nctId":"NCT01506882","phase":"PHASE3","title":"An Open Label Study of Levetiracetam Monotherapy in Patients With Newly Diagnosed Focal Epilepsy","status":"COMPLETED","sponsor":"UCB Japan Co. Ltd.","startDate":"2011-12","conditions":"Epilepsy, Partial Onset Seizures","enrollment":71},{"nctId":"NCT00291655","phase":"PHASE3","title":"Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903).","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2006-06","conditions":"Epilepsy","enrollment":130},{"nctId":"NCT02429596","phase":"PHASE4","title":"A Trial of Generic Substitution of Antiepileptic Drugs","status":"UNKNOWN","sponsor":"IRCCS National Neurological Institute \"C. Mondino\" Foundation","startDate":"2012-05","conditions":"Epilepsy","enrollment":200},{"nctId":"NCT00105040","phase":"PHASE2","title":"A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-09","conditions":"Epilepsy, Partial","enrollment":87},{"nctId":"NCT00280696","phase":"PHASE3","title":"A Double-blind Confirmatory Trial of Levetiracetam in Epilepsy Patients With Partial Onset Seizures","status":"COMPLETED","sponsor":"UCB Japan Co. Ltd.","startDate":"2005-11","conditions":"Epilepsies, Partial","enrollment":352},{"nctId":"NCT00618436","phase":"PHASE4","title":"Assess Safety and Efficacy of Levetiracetam(LEV;Keppra)for Seizure Prevention","status":"COMPLETED","sponsor":"University of Cincinnati","startDate":"2007-08","conditions":"Traumatic Brain Injury, Subarachnoid Hemorrhage","enrollment":52},{"nctId":"NCT01491113","phase":"PHASE4","title":"Pharmacokinetic (PK) Study in Japanese Non-epileptic Renal Impaired Patients","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2011-11","conditions":"Healthy Subjects, Renal Impairments","enrollment":30},{"nctId":"NCT00152373","phase":"PHASE3","title":"Double-blind, Placebo-controlled Study of Levetiracetam in Adults With POS","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-07","conditions":"Epilepsy, Partial","enrollment":192},{"nctId":"NCT00160550","phase":"PHASE3","title":"Study to Evaluate the Safety and Efficacy of Levetiracetam in Patients Suffering From Idiopathic Generalized Epilepsy With Primary Generalized Tonic-clonic Seizures","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2001-09","conditions":"Generalized Convulsive Epilepsy","enrollment":154},{"nctId":"NCT00150774","phase":"PHASE3","title":"Levetiracetam as add-on Treatment of Myoclonic Jerks in Adolescents + Adults","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2001-11","conditions":"Generalized Convulsive Epilepsy","enrollment":116},{"nctId":"NCT00438451","phase":"PHASE4","title":"Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs","status":"COMPLETED","sponsor":"Johannes Gutenberg University Mainz","startDate":"2007-01","conditions":"Focal Epilepsy","enrollment":361},{"nctId":"NCT00152516","phase":"PHASE3","title":"Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset Seizures","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2004-10","conditions":"Epilepsy, Partial","enrollment":255},{"nctId":"NCT01618903","phase":"PHASE1","title":"An Open-label, Bioequivalence Study to Evaluate LEV Administered as a 45-min Intravenous Infusion and Same Dosage LEV Oral Tablet in Chinese","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2012-05","conditions":"Human Volunteers","enrollment":24},{"nctId":"NCT00535392","phase":"PHASE2","title":"Open-label Study of Levetiracetam Intravenous Infusion in Children (4-16 Years Old) With Epilepsy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2007-09","conditions":"Epilepsy","enrollment":33},{"nctId":"NCT00471744","phase":"PHASE3","title":"HEAD-Study Optimizing the Treatment of Children With BECTS","status":"TERMINATED","sponsor":"Ludwig-Maximilians - University of Munich","startDate":"2006-06","conditions":"Epilepsy, Rolandic","enrollment":44},{"nctId":"NCT00542802","phase":"PHASE3","title":"Levetiracetam Versus Carbamazepine in Post-Stroke Late Onset Crisis","status":"UNKNOWN","sponsor":"Scienze Neurologiche Ospedaliere","startDate":"2007-09","conditions":"Epileptic Seizures, Stroke","enrollment":630}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ALTERED STATE OF CONSCIOUSNESS"},{"count":1,"reaction":"DRUG INEFFECTIVE"},{"count":1,"reaction":"ELECTROENCEPHALOGRAM ABNORMAL"},{"count":1,"reaction":"METAMORPHOPSIA"},{"count":1,"reaction":"VISUAL IMPAIRMENT"}],"_approvalHistory":[],"publicationCount":1302,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Keppra","E Keppra"],"phase":"marketed","status":"active","brandName":"Levetiracetam (LEV)","genericName":"Levetiracetam (LEV)","companyName":"UCB Japan Co. Ltd.","companyId":"ucb-japan-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levetiracetam (LEV) is a small molecule that modulates the synaptic vesicle glycoprotein 2A, a protein involved in neurotransmitter release. It is used to treat conditions such as epilepsy, partial seizures, and status epilepticus, and has been studied in various clinical trials, including those involving patients with renal impairments.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}